The Guiding Value of Tumor Micronecrosis for Using Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas
Sponsor study identifier
observational
900
1 country
2
Study Start
April 30, 2020
Actual (reported)Primary Completion
January 1, 2022
Actual (reported)Study Completion
April 14, 2022
Actual (reported)Micronecrosis is a novel pathological feature of hepatocellular carcinoma (HCC). This study was aimed at evaluating the effect of tumor micronecrosis on postoperative transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinomas, and further exploring the value of micronecrosis for guiding TACE in HCC management.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 14, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 30, 2020
Actual (reported)January 1, 2022
Actual (reported)April 14, 2022
Actual (reported)April 22, 2022
Actual (reported)April 28, 2022
Actual (reported)overall survival
the number of months from the date of surgery to the date of the last follow-up visit or time of death.
after liver resection until June 1, 2020
disease-free survival
after liver resection until June 1, 2020
transcatheter arterial chemoembolization after liver resection
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
From June 2014 to April 2018, HCC patients who underwent liver resection in our center were retrospectively reviewed.
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310009, China
the First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
900 participants (actual enrollment reported by the registry).
First Submitted
April 22, 2022
First Posted
April 28, 2022
Study Start
April 30, 2020
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
January 1, 2022
Actual (reported)Study Completion
April 14, 2022
Actual (reported)Last Updated
February 14, 2023
Record last verified: 2023-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: